Crowley John F
Crowley John F's purchase track record
Crowley John F has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 1/12/2022 | TRDA | $49K | -23.2% | +5.6% | -19.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
TRDA sees institutional interest from NVIDIA and Merck. The Benzinga report notes that institutional investors linked to NVIDIA and Merck have increased their positions in TRDA. This activity signals growing confidence in the company’s pipeline and may attract additional attention from other investors. The move comes as TRDA trades near the lower end of its 52‑week range, providing a potential entry point for those monitoring the stock.
Transaction History
| NTLA | ▲ Buy | Grant | 4,425 | $0 | 6/14/2023 | View on chart |
| NTLA | ▲ Buy | Grant | 5,197 | $0 | 6/14/2022 | View on chart |
| TRDA | ▲ Buy | Open Market | 5,000 | $49K | 1/12/2022 | View on chart |
| NTLA | ▲ Buy | Option Exercise | 2,500 | $47K | 10/11/2021 | View on chart |
| NTLA | ▼ Sell | Open Market | 2,500 | $299K | 10/11/2021 | View on chart |
| NTLA | ▲ Buy | Option Exercise | 10,000 | $188K | 10/5/2021 | View on chart |
| NTLA | ▼ Sell | Open Market | 1,280 | $165K | 10/5/2021 | View on chart |
| NTLA | ▼ Sell | Open Market | 2,915 | $379K | 10/5/2021 | View on chart |
| NTLA | ▼ Sell | Open Market | 3,759 | $492K | 10/5/2021 | View on chart |
| NTLA | ▼ Sell | Open Market | 200 | $27K | 10/5/2021 | View on chart |
| NTLA | ▼ Sell | Open Market | 1,846 | $243K | 10/5/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Intellia Therapeutics Appoints New Chief Medical Officer
Intellia Therapeutics announced the appointment of Jing L. Marantz as its new Chief Medical Officer. This leadership change occurred as the stock recently rose 7.6%, moving away from recent support levels. The news highlights a strategic shift in the company's medical leadership during a period of increased market activity.
Intellia Therapeutics Appoints New Chief Medical Officer. Intellia Therapeutics announced the appointment of Jing L. Marantz as its new Chief Medical Officer. This leadership change occurred as the stock recently rose 7.6%, moving away from recent support levels. The news highlights a strategic shift in the company's medical leadership during a period of increased market activity.